source
stringlengths 2
222
| date
stringlengths 19
19
| url
stringlengths 22
853
⌀ | text
stringlengths 0
10k
⌀ | title
stringlengths 0
701
| context_id
stringlengths 1
9
| document_id
stringclasses 2
values | document_type
stringclasses 2
values |
|---|---|---|---|---|---|---|---|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-30 05:44:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 30, 2021) - THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT A CLASS ACTION LAWSUIT HAS COMMENCED ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN"). THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING..IF YOU SUFFERED A LOSS, CONTACT US AT THE LINK BELOW. THERE IS...
|
ZY LAWSUIT: THE LAW OFFICES OF VINCENT WONG NOTIFY INVESTORS OF A CLASS ACTION LAWSUIT INVOLVING ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 22:23:00
| null |
NEW YORK, SEPT. 29, 2021 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF ZYMERGEN, INC. ("ZYMERGEN OR THE "COMPANY") (NASDAQ: ZY).
|
SHAREHOLDER ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF ZYMERGEN, INC. - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 19:43:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 29, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 16:10:00
| null |
SAN DIEGO, CALIFORNIA--(NEWSFILE CORP. - SEPTEMBER 29, 2021) - ROBBINS GELLER RUDMAN & DOWD LLP ANNOUNCES THAT PURCHASERS OF ZYMERGEN INC. (NASDAQ: ZY) COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO") HAVE UNTIL THIS UPCOMING MONDAY, OCTOBER 4, 2021 TO SEEK APPOINTMENT AS LEAD PLAINTIFF. THE ZYMERGEN CLASS ACTION LAWSUIT (SHANKAR V. ZYMERGEN INC., NO. 21-CV-06028)...
|
ZY MONDAY DEADLINE: INVESTORS WITH SUBSTANTIAL LOSSES HAVE OPPORTUNITY TO LEAD THE ZYMERGEN INC. CLASS ACTION LAWSUIT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 16:00:00
| null |
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - SEPTEMBER 29, 2021) - THE THORNTON LAW FIRM ALERTS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF INVESTORS OF ZYMERGEN INC. (NASDAQ: ZY). THE CASE IS CURRENTLY IN THE LEAD PLAINTIFF STAGE. INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING MAY CONTACT THE THORNTON LAW FIRM'S INVESTOR PROTECTION...
|
ZY INVESTOR ALERT: SHAREHOLDER CLASS ACTION LAWSUIT FILED
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 14:40:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 29, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 11:30:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 29, 2021 / THE KLEIN LAW FIRM ANNOUNCES THAT CLASS ACTION COMPLAINTS HAVE BEEN FILED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING COMPANIES. THERE IS NO COST TO PARTICIPATE IN THE SUIT.
|
THE KLEIN LAW FIRM REMINDS INVESTORS OF CLASS ACTIONS ON BEHALF OF SHAREHOLDERS OF ATVI, ZY AND SLQT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-29 10:41:00
| null |
SAN FRANCISCO, CALIFORNIA--(NEWSFILE CORP. - SEPTEMBER 29, 2021) - HAGENS BERMAN URGES ZYMERGEN INC. (NASDAQ: ZY) INVESTORS WITH SIGNIFICANT LOSSES TO SUBMIT YOUR LOSSES NOW.CLASS PERIOD: APR. 20, 2021 - AUG. 4, 2021LEAD PLAINTIFF DEADLINE: OCT. 4, 2021VISIT: WWW.HBSSLAW.COM/INVESTOR-FRAUD/ZY CONTACT AN ATTORNEY NOW: ZY@HBSSLAW.COM 844-916-0895ZYMERGEN INC. (ZY) SECURITIES CLASS ACTION: THE CASE ARISES FROM ZYMERGEN'S MISREPRESENTATIONS IN ITS REGISTRATION STATEMENT FOR ITS APR. 23, 2021, IPO CONCERNING...
|
ZY INVESTOR DEADLINE: HAGENS BERMAN ENCOURAGES ZYMERGEN (ZY) INVESTORS WITH LOSSES TO CONTACT FIRM'S ATTORNEYS BEFORE OCTOBER 4TH DEADLINE IN SECURITIES FRAUD LAWSUIT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-28 21:05:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 28, 2021) - THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT A CLASS ACTION LAWSUIT HAS COMMENCED IN THE ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) . THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.IF YOU SUFFERED A LOSS, CONTACT US AT THE LINK...
|
ZY LAWSUIT: THE LAW OFFICES OF VINCENT WONG NOTIFY INVESTORS OF A CLASS ACTION LAWSUIT INVOLVING ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-28 18:53:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 28, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-28 16:51:00
| null |
LOS ANGELES, CALIFORNIA--(NEWSFILE CORP. - SEPTEMBER 28, 2021) - THE SCHALL LAW FIRM, A NATIONAL SHAREHOLDER RIGHTS LITIGATION FIRM, ANNOUNCES THE FILING OF A CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. ("ZYMERGEN" OR "THE COMPANY") (NASDAQ: ZY) FOR VIOLATIONS OF THE FEDERAL SECURITIES LAWS.INVESTORS WHO PURCHASED THE COMPANY'S SHARES PURSUANT AND/OR TRACEABLE TO THE COMPANY'S INITIAL PUBLIC OFFERING CONDUCTED IN APRIL 2021 (THE "IPO"), ARE ENCOURAGED TO CONTACT THE FIRM BEFORE OCTOBER 4, 2021. ...
|
MONDAY DEADLINE REMINDER: THE SCHALL LAW FIRM ANNOUNCES THE FILING OF A CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. AND ENCOURAGES INVESTORS WITH LOSSES IN EXCESS OF $100,000 TO CONTACT THE FIRM
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-28 12:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 28, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-28 08:57:00
| null |
RADNOR, PA., SEPT. 28, 2021 /PRNEWSWIRE/ -- SEPTEMBER 28, 2021 – THE LAW FIRM OF KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS INVESTORS THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") ON BEHALF OF THOSE WHO PURCHASED OR ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO").
|
ZYMERGEN INC. CLASS ACTION REMINDER: KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS SHAREHOLDERS OF DEADLINE IN SECURITIES FRAUD CLASS ACTION LAWSUIT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-27 17:05:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 27, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-27 13:00:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 27, 2021 / JAKUBOWITZ LAW ANNOUNCES THAT SECURITIES FRAUD CLASS ACTION LAWSUITS HAVE COMMENCED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING PUBLICLY-TRADED COMPANIES WHO PURCHASED SHARES WITHIN THE CLASS PERIODS LISTED BELOW. SHAREHOLDERS INTERESTED IN REPRESENTING THE CLASS OF WRONGED SHAREHOLDERS HAVE UNTIL THE LEAD PLAINTIFF DEADLINE TO PETITION THE COURT.
|
LAWSUITS FILED AGAINST ZY, YALA AND SAVA - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-27 12:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 27, 2021) - BERNSTEIN LIEBHARD, A NATIONALLY ACCLAIMED INVESTOR RIGHTS LAW FIRM, REMINDS INVESTORS OF THE DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN A SECURITIES CLASS ACTION LAWSUIT THAT HAS BEEN FILED ON BEHALF OF INVESTORS WHO PURCHASED OR ACQUIRED THE SECURITIES OF ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) FROM APRIL 20, 2021 THROUGH AUGUST 4, 2021 (THE "CLASS PERIOD"). THE LAWSUIT FILED IN THE...
|
ZYMERGEN INC. (ZY) CLASS ACTION LAWSUIT FILING DEADLINE: BERNSTEIN LIEBHARD LLP REMINDS INVESTORS OF THE DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN A SECURITIES CLASS ACTION LAWSUIT AGAINST ZYMERGEN, INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-27 09:37:00
| null |
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - SEPTEMBER 27, 2021) - BERGER MONTAGUE IS INVESTIGATING SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY"). THE FIRM IS INVESTIGATING THESE CLAIMS ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN SECURITIES (NASDAQ: ZY) ON OR TRACEABLE TO THE COMPANY'S INITIAL PUBLIC OFFERING (IPO) ON APRIL 23, 2021. IF YOU PURCHASED ZYMERGEN SECURITIES ON OR TRACEABLE TO THE IPO AND WOULD LIKE TO LEARN MORE ABOUT BERGER MONTAGUE'S INVESTIGATION, PLEASE CONTACT...
|
ZYMERGEN INC. STOCK: BERGER MONTAGUE INVESTIGATES SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN (ZY); LEAD PLAINTIFF DEADLINE IS OCTOBER 4, 2021
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-26 23:45:00
| null |
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - SEPTEMBER 26, 2021) - THE THORNTON LAW FIRM ALERTS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF INVESTORS OF ZYMERGEN INC. (NASDAQ: ZY). THE CASE IS CURRENTLY IN THE LEAD PLAINTIFF STAGE. INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING MAY CONTACT THE THORNTON LAW FIRM'S INVESTOR PROTECTION...
|
ZY INVESTOR ALERT: SHAREHOLDER LAWSUIT FILED
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-26 08:51:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 26, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS BETWEEN...
|
ZYMERGEN CLASS ACTION REMINDER
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-25 18:33:00
| null |
NEW YORK, SEPT. 25, 2021 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.
|
ROSEN, A TOP RANKED LAW FIRM, ENCOURAGES ZYMERGEN INC. INVESTORS WITH LOSSES SECURE COUNSEL BEFORE IMPORTANT OCTOBER 4 DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-24 14:15:00
| null |
NEW YORK, SEPT. 24, 2021 /PRNEWSWIRE/ -- BERNSTEIN LIEBHARD, A NATIONALLY ACCLAIMED INVESTOR RIGHTS LAW FIRM, REMINDS INVESTORS OF THE DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN A SECURITIES CLASS ACTION LAWSUIT THAT HAS BEEN FILED ON BEHALF OF INVESTORS WHO PURCHASED OR ACQUIRED THE SECURITIES OF ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) FROM APRIL 20, 2021 THROUGH AUGUST 4, 2021 (THE "CLASS PERIOD").
|
ZYMERGEN INC. (NASDAQ: ZY) OCTOBER 4, 2021 SHAREHOLDER FILING DEADLINE: BERNSTEIN LIEBHARD LLP REMINDS INVESTORS OF THE DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN A SECURITIES CLASS ACTION LAWSUIT AGAINST ZYMERGEN, INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-24 13:00:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 24, 2021 / THE SECURITIES LITIGATION LAW FIRM OF THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE ON BEHALF OF SHAREHOLDERS IN THE FOLLOWING PUBLICLY TRADED COMPANIES. SHAREHOLDERS WHO PURCHASED SHARES IN THE FOLLOWING COMPANIES DURING THE DATES LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.
|
THE GROSS LAW FIRM ANNOUNCES CLASS ACTIONS ON BEHALF OF SHAREHOLDERS OF AHCO, ZY AND VIEW
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-24 11:48:00
| null |
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - SEPTEMBER 24, 2021) - BERGER MONTAGUE IS INVESTIGATING SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY"). THE FIRM IS INVESTIGATING THESE CLAIMS ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN SECURITIES (NASDAQ: ZY) ON OR TRACEABLE TO THE COMPANY'S INITIAL PUBLIC OFFERING (IPO) ON APRIL 23, 2021. IF YOU PURCHASED ZYMERGEN SECURITIES ON OR TRACEABLE TO THE IPO AND WOULD LIKE TO LEARN MORE ABOUT BERGER MONTAGUE'S INVESTIGATION, PLEASE CONTACT...
|
ZYMERGEN INC. STOCK: BERGER MONTAGUE INVESTIGATES SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN (ZY); LEAD PLAINTIFF DEADLINE IS OCTOBER 4, 2021
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-24 11:45:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 24, 2021 / LEVI & KORSINSKY, LLP ANNOUNCES THAT CLASS ACTION LAWSUITS HAVE COMMENCED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING PUBLICLY-TRADED COMPANIES. SHAREHOLDERS INTERESTED IN SERVING AS LEAD PLAINTIFF HAVE UNTIL THE DEADLINES LISTED TO PETITION THE COURT.
|
CLASS ACTION UPDATE FOR ATVI, ZY AND VIEW: LEVI & KORSINSKY, LLP REMINDS INVESTORS OF CLASS ACTIONS ON BEHALF OF SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-24 05:49:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 24, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION LAWSUIT HAS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 19:56:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - JAKUBOWITZ LAW ANNOUNCES THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS COMMENCED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY).CLICK HERE FOR MORE DETAILS:HTTPS://CLAIMYOURLOSS.COM/SECURITIES/ZYMERGEN-INC-LOSS-SUBMISSION-FORM/?ID=19821&FROM=5
|
ZY LAWSUIT FILED: JAKUBOWITZ LAW PURSUES CLAIMS ON BEHALF OF ZYMERGEN INC. SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 18:27:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS...
|
ZYMERGEN SHAREHOLDER ALERT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 17:41:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - THE SECURITIES LITIGATION LAW FIRM OF THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC (NASDAQ: ZY).SHAREHOLDERS WHO PURCHASED SHARES OF ZY DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT. APPOINTMENT AS LEAD PLAINTIFF IS NOT REQUIRED TO PARTAKE IN ANY RECOVERY.CONTACT US HERE:HTTPS://SECURITIESCLASSLAW.COM/SECURITIES/ZYMERGEN-INC-LOSS-SUBMISSION-FORM/?ID=19808&FROM=5
|
SHAREHOLDER ALERT: THE GROSS LAW FIRM NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - (ZY)
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 13:05:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT A CLASS ACTION LAWSUIT HAS COMMENCED IN THE ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) . THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING..IF YOU SUFFERED A LOSS, CONTACT US AT...
|
ZY LAWSUIT: THE LAW OFFICES OF VINCENT WONG NOTIFY INVESTORS OF A CLASS ACTION LAWSUIT INVOLVING ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 11:30:00
| null |
LOS ANGELES, SEPT. 23, 2021 /PRNEWSWIRE/ -- THE LAW OFFICES OF FRANK R.
|
THE LAW OFFICES OF FRANK R. CRUZ ANNOUNCES THE FILING OF A SECURITIES CLASS ACTION ON BEHALF OF ZYMERGEN INC. (ZY) INVESTORS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 10:31:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-23 05:32:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 23, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION LAWSUIT HAS...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-22 15:25:00
| null |
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - SEPTEMBER 22, 2021) - THE THORNTON LAW FIRM ALERTS INVESTORS WHO PURCHASED ZYMERGEN INC. COMMON STOCK (NASDAQ: ZY) PURSUANT OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING MAY SEEK TO PARTICIPATE IN THE CASE AS A LEAD PLAINTIFF. INTERESTED INVESTORS MAY CONTACT THE THORNTON LAW FIRM'S INVESTOR PROTECTION TEAM BY VISITING WWW.TENLAW.COM/CASES/ZYMERGEN FOR MORE INFORMATION. INVESTORS MAY ALSO EMAIL...
|
ZY INVESTOR ALERT: SHAREHOLDER CLASS ACTION LAWSUIT FILED
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-22 10:51:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 22, 2021) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED ZYMERGEN SECURITIES PURSUANT AND/OR TRACEABLE TO...
|
ROSEN, RECOGNIZED INVESTOR COUNSEL, ENCOURAGES ZYMERGEN INC. INVESTORS SECURE COUNSEL BEFORE IMPORTANT OCTOBER 4 DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 20:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 21, 2021) - THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT A CLASS ACTION LAWSUIT HAS COMMENCED IN THE ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) . THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING..IF YOU SUFFERED A LOSS, CONTACT US AT THE...
|
ZY LAWSUIT: THE LAW OFFICES OF VINCENT WONG NOTIFY INVESTORS OF A CLASS ACTION LAWSUIT INVOLVING ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 18:43:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 21, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS BETWEEN...
|
ZYMERGEN SHAREHOLDER ALERT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 17:18:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 21, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 15:45:00
| null |
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - SEPTEMBER 21, 2021) - BERGER MONTAGUE IS INVESTIGATING SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY"). THE FIRM IS INVESTIGATING THESE CLAIMS ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN SECURITIES (NASDAQ: ZY) ON OR TRACEABLE TO THE COMPANY'S INITIAL PUBLIC OFFERING (IPO) ON APRIL 23, 2021.IF YOU PURCHASED ZYMERGEN SECURITIES ON OR TRACEABLE TO THE IPO AND WOULD LIKE TO LEARN MORE ABOUT BERGER MONTAGUE'S INVESTIGATION, PLEASE CONTACT...
|
ZYMERGEN INC. STOCK: BERGER MONTAGUE INVESTIGATES SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN (ZY); LEAD PLAINTIFF DEADLINE IS OCTOBER 4, 2021
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 12:50:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 21, 2021 / JAKUBOWITZ LAW ANNOUNCES THAT SECURITIES FRAUD CLASS ACTION LAWSUITS HAVE COMMENCED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING PUBLICLY-TRADED COMPANIES WHO PURCHASED SHARES WITHIN THE CLASS PERIODS LISTED BELOW. SHAREHOLDERS INTERESTED IN REPRESENTING THE CLASS OF WRONGED SHAREHOLDERS HAVE UNTIL THE LEAD PLAINTIFF DEADLINE TO PETITION THE COURT.
|
LAWSUITS FILED AGAINST ZY, SLQT AND ATIP - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-21 05:23:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 21, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 21:03:00
| null |
NEW YORK, SEPT. 20, 2021 /PRNEWSWIRE/ -- WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.
|
ROSEN, A GLOBAL AND LEADING LAW FIRM, ENCOURAGES ZYMERGEN INC. INVESTORS WITH LOSSES TO SECURE COUNSEL BEFORE IMPORTANT OCTOBER 4 DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 13:45:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 20, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 11:45:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 20, 2021 / JAKUBOWITZ LAW ANNOUNCES THAT SECURITIES FRAUD CLASS ACTION LAWSUITS HAVE COMMENCED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING PUBLICLY-TRADED COMPANIES WHO PURCHASED SHARES WITHIN THE CLASS PERIODS LISTED BELOW. SHAREHOLDERS INTERESTED IN REPRESENTING THE CLASS OF WRONGED SHAREHOLDERS HAVE UNTIL THE LEAD PLAINTIFF DEADLINE TO PETITION THE COURT.
|
LAWSUITS FILED AGAINST COIN, ZY AND HYRE - JAKUBOWITZ LAW PURSUES SHAREHOLDERS CLAIMS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 11:00:00
| null |
BENSALEM, PA., SEPT. 20, 2021 /PRNEWSWIRE/ -- LAW OFFICES OF HOWARD G.
|
DEADLINE REMINDER: LAW OFFICES OF HOWARD G. SMITH REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. (ZY)
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-20 08:58:00
| null |
RADNOR, PENNSYLVANIA--(NEWSFILE CORP. - SEPTEMBER 20, 2021) - THE LAW FIRM OF KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS INVESTORS THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") ON BEHALF OF THOSE WHO PURCHASED OR ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO").DEADLINE REMINDER: ...
|
INVESTOR REMINDER: KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS INVESTORS OF SECURITIES FRAUD CLASS ACTION LAWSUIT FILED AGAINST ZYMERGEN INC. - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-19 10:21:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 19, 2021 / LEVI & KORSINSKY, LLP ANNOUNCES THAT CLASS ACTION LAWSUITS HAVE COMMENCED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING PUBLICLY-TRADED COMPANIES. SHAREHOLDERS INTERESTED IN SERVING AS LEAD PLAINTIFF HAVE UNTIL THE DEADLINES LISTED TO PETITION THE COURT.
|
CLASS ACTION UPDATE FOR ZY, LIVE AND SLQT: LEVI & KORSINSKY, LLP REMINDS INVESTORS OF CLASS ACTIONS ON BEHALF OF SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-19 08:51:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 19, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS BETWEEN...
|
ZYMERGEN CLASS ACTION REMINDER
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 18:22:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 17, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 16:56:00
| null |
RADNOR, PA., SEPT. 17, 2021 /PRNEWSWIRE/ -- THE LAW FIRM OF KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ("ZYMERGEN") THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF THOSE WHO PURCHASED OR ACQUIRED ZYMERGEN COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO").
|
KESSLER TOPAZ MELTZER & CHECK, LLP REMINDS INVESTORS OF DEADLINE FOR SECURITIES FRAUD CLASS ACTION LAWSUIT FILED AGAINST ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 15:15:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 17, 2021) - THE FOLLOWING STATEMENT IS BEING ISSUED BY LEVI & KORSINSKY, LLP:TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SECURITIES OF ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.. YOU ARE HEREBY NOTIFIED THAT A SECURITIES CLASS ACTION...
|
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP NOTIFIES SHAREHOLDERS OF ZYMERGEN INC. OF A CLASS ACTION LAWSUIT AND A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 13:23:00
| null |
PHILADELPHIA, PENNSYLVANIA--(NEWSFILE CORP. - SEPTEMBER 17, 2021) - BERGER MONTAGUE IS INVESTIGATING SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY"). THE FIRM IS INVESTIGATING THESE CLAIMS ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN SECURITIES (NASDAQ: ZY) ON OR TRACEABLE TO THE COMPANY'S INITIAL PUBLIC OFFERING (IPO) ON APRIL 23, 2021.IF YOU PURCHASED ZYMERGEN SECURITIES ON OR TRACEABLE TO THE IPO AND WOULD LIKE TO LEARN MORE ABOUT BERGER MONTAGUE'S INVESTIGATION, PLEASE CONTACT ATTORNEYS...
|
ZYMERGEN INC. STOCK: BERGER MONTAGUE INVESTIGATES SECURITIES FRAUD CLAIMS AGAINST ZYMERGEN (ZY); LEAD PLAINTIFF DEADLINE IS OCTOBER 4, 2021
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 13:00:00
| null |
LOS ANGELES, SEPT. 17, 2021 /PRNEWSWIRE/ -- GLANCY PRONGAY & MURRAY LLP ("GPM") REMINDS INVESTORS OF THE UPCOMING OCTOBER 4, 2021 DEADLINE TO FILE A LEAD PLAINTIFF MOTION IN THE CLASS ACTION FILED ON BEHALF OF INVESTORS WHO PURCHASED OR OTHERWISE ACQUIRED ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING ("IPO" OR THE "OFFERING").
|
GLANCY PRONGAY & MURRAY LLP REMINDS INVESTORS OF LOOMING DEADLINE IN THE CLASS ACTION LAWSUIT AGAINST ZYMERGEN INC. (ZY)
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 12:40:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 17, 2021 / THE SECURITIES LITIGATION LAW FIRM OF THE GROSS LAW FIRM ISSUES THE FOLLOWING NOTICE ON BEHALF OF SHAREHOLDERS IN THE FOLLOWING PUBLICLY TRADED COMPANIES. SHAREHOLDERS WHO PURCHASED SHARES IN THE FOLLOWING COMPANIES DURING THE DATES LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENT.
|
THE GROSS LAW FIRM ANNOUNCES CLASS ACTIONS ON BEHALF OF SHAREHOLDERS OF COIN, ZY AND WDH
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 12:00:00
| null |
BOSTON, MASSACHUSETTS--(NEWSFILE CORP. - SEPTEMBER 17, 2021) - THE THORNTON LAW FIRM ALERTS INVESTORS THAT A CLASS ACTION LAWSUIT HAS BEEN FILED ON BEHALF OF INVESTORS OF ZYMERGEN INC. (NASDAQ: ZY). THE CASE IS CURRENTLY IN THE LEAD PLAINTIFF STAGE. INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT OR TRACEABLE TO THE REGISTRATION STATEMENT AND PROSPECTUS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING MAY CONTACT THE THORNTON LAW FIRM'S INVESTOR PROTECTION...
|
ZY INVESTOR ALERT: CLASS ACTION LAWSUIT FILED
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-17 06:00:00
| null |
NEW YORK, NY / ACCESSWIRE / SEPTEMBER 17, 2021 / THE KLEIN LAW FIRM ANNOUNCES THAT CLASS ACTION COMPLAINTS HAVE BEEN FILED ON BEHALF OF SHAREHOLDERS OF THE FOLLOWING COMPANIES. THERE IS NO COST TO PARTICIPATE IN THE SUIT.
|
THE KLEIN LAW FIRM REMINDS INVESTORS OF CLASS ACTIONS ON BEHALF OF SHAREHOLDERS OF COIN, PLL AND ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-16 18:27:00
| null |
SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES EXCEEDING $50,000 IN ZYMERGEN TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONSNEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 16, 2021) - FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST ZYMERGEN INC. ("ZYMERGEN" OR THE "COMPANY") (NASDAQ: ZY) AND REMINDS INVESTORS OF THE OCTOBER 4, 2021 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. IF YOU SUFFERED LOSSES EXCEEDING $50,000 INVESTING IN ZYMERGEN STOCK OR OPTIONS BETWEEN...
|
ZYMERGEN SHAREHOLDER ALERT
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-16 09:36:00
| null |
SAN FRANCISCO, CALIFORNIA--(NEWSFILE CORP. - SEPTEMBER 16, 2021) - HAGENS BERMAN URGES ZYMERGEN INC. (NASDAQ: ZY) INVESTORS WITH SIGNIFICANT LOSSES TO SUBMIT YOUR LOSSES NOW. CLASS PERIOD: APR. 20, 2021 - AUG. 4, 2021LEAD PLAINTIFF DEADLINE: OCT. 4, 2021VISIT: WWW.HBSSLAW.COM/INVESTOR-FRAUD/ZYCONTACT AN ATTORNEY NOW: ZY@HBSSLAW.COM844-916-0895ZYMERGEN INC. (ZY) SECURITIES CLASS ACTION: THE CASE ARISES FROM ZYMERGEN'S MISREPRESENTATIONS IN ITS REGISTRATION STATEMENT FOR ITS APR. 23, 2021, IPO CONCERNING HYALINE, THE COMPANY'S PRIMARY
|
HAGENS BERMAN ENCOURAGES ZYMERGEN (ZY) INVESTORS WITH LOSSES TO CONTACT FIRM'S ATTORNEYS NOW, LEAD PLAINTIFF OPPORTUNITY IN SECURITIES CLASS ACTION
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-15 17:53:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 15, 2021) - WHY: ROSEN LAW FIRM, A GLOBAL INVESTOR RIGHTS LAW FIRM, REMINDS PURCHASERS OF THE SECURITIES OF ZYMERGEN INC. (NASDAQ: ZY) PURSUANT AND/OR TRACEABLE TO THE REGISTRATION STATEMENT AND RELATED PROSPECTUS (COLLECTIVELY, THE "REGISTRATION STATEMENT") ISSUED IN CONNECTION WITH ZYMERGEN'S APRIL 2021 INITIAL PUBLIC OFFERING (THE "IPO"), OF THE IMPORTANT OCTOBER 4, 2021 LEAD PLAINTIFF DEADLINE.SO WHAT: IF YOU PURCHASED ZYMERGEN SECURITIES PURSUANT AND/OR TRACEABLE TO...
|
ROSEN, A LEADING AND LONGSTANDING LAW FIRM, ENCOURAGES ZYMERGEN INC. INVESTORS WITH LOSSES EXCEEDING $100K TO SECURE COUNSEL BEFORE IMPORTANT OCTOBER 4 DEADLINE IN SECURITIES CLASS ACTION - ZY
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-15 14:57:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 15, 2021) - THE LAW OFFICES OF VINCENT WONG ANNOUNCE THAT A CLASS ACTION LAWSUIT HAS COMMENCED IN THE ON BEHALF OF INVESTORS WHO PURCHASED ZYMERGEN INC. ("ZYMERGEN") (NASDAQ: ZY) . THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING..IF YOU SUFFERED A LOSS, CONTACT US AT THE...
|
ZY LAWSUIT: THE LAW OFFICES OF VINCENT WONG NOTIFY INVESTORS OF A CLASS ACTION LAWSUIT INVOLVING ZYMERGEN INC.
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-15 12:44:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 15, 2021) - THE KLEIN LAW FIRM ANNOUNCES THAT A CLASS ACTION COMPLAINT HAS BEEN FILED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY) ALLEGING THAT THE COMPANY VIOLATED FEDERAL SECURITIES LAWS.THIS LAWSUIT IS ON BEHALF OF INVESTORS WHO PURCHASED ZY COMMON STOCK PURSUANT AND/OR TRACEABLE TO THE DOCUMENTS ISSUED IN CONNECTION WITH THE COMPANY'S APRIL 2021 INITIAL PUBLIC OFFERING.LEAD PLAINTIFF DEADLINE: OCTOBER 4, 2021NO OBLIGATION OR...
|
ZY ALERT: THE KLEIN LAW FIRM ANNOUNCES A LEAD PLAINTIFF DEADLINE OF OCTOBER 4, 2021 IN THE CLASS ACTION FILED ON BEHALF OF ZYMERGEN INC. LIMITED SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2021-09-15 05:28:00
| null |
NEW YORK, NEW YORK--(NEWSFILE CORP. - SEPTEMBER 15, 2021) - JAKUBOWITZ LAW ANNOUNCES THAT A SECURITIES FRAUD CLASS ACTION LAWSUIT HAS COMMENCED ON BEHALF OF SHAREHOLDERS OF ZYMERGEN INC. (NASDAQ: ZY).CLICK HERE FOR MORE DETAILS:HTTPS://CLAIMYOURLOSS.COM/SECURITIES/ZYMERGEN-INC-LOSS-SUBMISSION-FORM/?ID=19613&FROM=5
|
ZY LAWSUIT FILED: JAKUBOWITZ LAW PURSUES CLAIMS ON BEHALF OF ZYMERGEN INC. SHAREHOLDERS
|
ZY
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-29 16:05:00
| null |
VANCOUVER, BRITISH COLUMBIA, JUNE 29, 2023 (GLOBE NEWSWIRE) -- ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL, MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF MR. CARLOS E. CAMPOY TO ITS BOARD OF DIRECTORS EFFECTIVE AS OF JUNE 30, 2023. MR. CAMPOY BRINGS EXTENSIVE STRATEGIC AND FINANCIAL LEADERSHIP EXPERIENCE IN THE PHARMACEUTICAL AND BIOTECHNOLOGY SECTORS TO THE ZYMEWORKS BOARD OF DIRECTORS. HE WAS ALSO APPOINTED AS A MEMBER OF THE AUDIT COMMITTEE AND THE NOMINATING AND CORPORATE GOVERNANCE COMMITTEE OF THE BOARD OF DIRECTORS.
|
ZYMEWORKS APPOINTS NEW DIRECTOR
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-26 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA, JUNE 26, 2023 (GLOBE NEWSWIRE) -- ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL, MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT IT IS SET TO JOIN BOTH THE RUSSELL 3000®, RUSSELL 2000®, AND THE RUSSELL MICROCAP® INDEXES AT THE CONCLUSION OF THE 2023 RUSSELL INDEXES ANNUAL RECONSTITUTION, EFFECTIVE AFTER THE U.S. MARKET OPENS ON JUNE 26, 2023.
|
ZYMEWORKS SET TO JOIN RUSSELL 3000®, RUSSELL 2000®, AND RUSSELL MICROCAP® INDEXES
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-06-02 18:41:00
| null |
RESULTS PRESENTED TODAY AT ASCO 2023 AND CONCURRENTLY PUBLISHED IN THE LANCET ONCOLOGY DEMONSTRATE MEANINGFUL CLINICAL BENEFIT INCLUDING ANTITUMOR ACTIVITY, CONFIRMED OBJECTIVE RESPONSE RATE (CORR) OF 41.3%, MEDIAN DURATION OF RESPONSE (DOR) OF 12.9 MONTHS, AND MEDIAN PROGRESSION-FREE SURVIVAL (PFS) OF 5.5 MONTHS (MEDIAN STUDY FOLLOW-UP TIME OF 12.4 MONTHS) BILIARY TRACT CANCERS (BTC) ARE AN AGGRESSIVE GROUP OF CANCERS WITH NO CURRENTLY APPROVED HER2-TARGETED TREATMENT OPTION JAZZ TO HOST KOL INVESTOR WEBCAST JUNE 2, 2023, AT 6:45 P.M. CT TO REVIEW ZANIDATAMAB BTC DATA DUBLIN AND VANCOUVER, BC , JUNE 2, 2023 /PRNEWSWIRE/ -- JAZZ PHARMACEUTICALS PLC (NASDAQ: JAZZ) AND ZYMEWORKS INC. (NASDAQ: ZYME) TODAY PRESENTED POSITIVE PIVOTAL TRIAL DATA, INCLUDING NEW DATA ON PROGRESSION-FREE SURVIVAL (PFS), FROM THE PHASE 2B HERIZON-BTC-01 TRIAL OF THE BISPECIFIC ANTIBODY ZANIDATAMAB IN PREVIOUSLY TREATED HER2-AMPLIFIED BILIARY TRACT CANCERS (BTC).
|
JAZZ PHARMACEUTICALS AND ZYMEWORKS PRESENT POSITIVE PIVOTAL PHASE 2B TRIAL DATA AT ASCO 2023 EVALUATING ZANIDATAMAB IN HER2-AMPLIFIED BILIARY TRACT CANCERS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-05-18 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA, MAY 18, 2023 (GLOBE NEWSWIRE) -- ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL, MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE DEPARTURE OF NEIL KLOMPAS, PRESIDENT AND CHIEF OPERATING OFFICER.
|
ZYMEWORKS ANNOUNCES DEPARTURE OF NEIL KLOMPAS, PRESIDENT AND CHIEF OPERATING OFFICER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-18 16:05:00
| null |
● ZW191 DEMONSTRATES STRONG RESPONSES IN FRΑ-LOW EXPRESSING PATIENT-DERIVED XENOGRAFT (PDX) MODELS WITH FAVORABLE PHARMACOKINETIC AND SAFETY PROFILES ● ZW171 INDUCED POTENT PREFERENTIAL KILLING OF CANCER CELLS AND POTENTIAL TO MITIGATE RISK OF ON-TARGET OFF-TUMOR TOXICITY, PERIPHERAL T CELL ACTIVATION, AND CYTOKINE-RELEASE SYNDROME ● ZW251 EXHIBITS DESIRED TARGET-MEDIATED ACTIVITY IN VITRO AND ROBUST ANTI-TUMOR ACTIVITY IN PDX MODELS ● MANAGEMENT WILL HOST CONFERENCE CALL TODAY AT 6:30 PM EASTERN DAYLIGHT TIME (EDT)
|
ZYMEWORKS PRESENTS NEW DATA FROM MULTIPLE PRECLINICAL AND CLINICAL DEVELOPMENT PROGRAMS AT THE 2023 AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-04-10 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL, MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE APPOINTMENT OF DEREK J. MILLER TO ITS BOARD OF DIRECTORS EFFECTIVE APRIL 10, 2023. MR. MILLER BRINGS EXTENSIVE COMMERCIAL, CORPORATE AND BUSINESS DEVELOPMENT, AND SENIOR LEADERSHIP EXPERIENCE IN ONCOLOGY TO THE ZYMEWORKS BOARD OF DIRECTORS.
|
ZYMEWORKS ANNOUNCES APPOINTMENT OF DEREK J. MILLER TO ITS BOARD OF DIRECTORS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-03-07 16:05:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 AND PROVIDED A SUMMARY OF RECENT BUSINESS HIGHLIGHTS.
|
ZYMEWORKS REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-19 07:45:00
| null |
RESULTS PRESENTED TODAY AT ASCO GI INCLUDE FIRST OVERALL SURVIVAL (OS) DATA FOR ZANIDATAMAB, OVERALL CONFIRMED OBJECTIVE RESPONSE RATE (CORR) OF 79%, DISEASE CONTROL RATE (DCR) OF 92%, AND MEDIAN PROGRESSION-FREE SURVIVAL (MPFS) OF 12.5 MONTHS ONGOING PHASE 3 RANDOMIZED CLINICAL TRIAL, HERIZON-GEA-01, HAS THE POTENTIAL TO SUPPORT REGULATORY SUBMISSIONS FOR ZANIDATAMAB IN COMBINATION WITH CHEMOTHERAPY AS A THERAPEUTIC OPTION FOR PATIENTS WITH ADVANCED HER2-EXPRESSING METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (MGEA) DUBLIN AND VANCOUVER, BC , JAN. 19, 2023 /PRNEWSWIRE/ -- JAZZ PHARMACEUTICALS PLC (NASDAQ: JAZZ) AND ZYMEWORKS INC. (NASDAQ: ZYME) TODAY ANNOUNCED TOLERABILITY AND EFFICACY RESULTS, INCLUDING THE FIRST OVERALL SURVIVAL (OS) DATA, FROM A PHASE 2 TRIAL EXAMINING ZANIDATAMAB, AN INVESTIGATIONAL HER2-TARGETED BISPECIFIC ANTIBODY, IN COMBINATION WITH CHEMOTHERAPY, IN FIRST-LINE PATIENTS WITH HER2-EXPRESSING METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA (MGEA). THE PRELIMINARY RESULTS SHOWED THAT, AT THE TIME OF ANALYSIS, THE MEDIAN OS HAD NOT YET BEEN REACHED WITH A MEDIAN DURATION OF STUDY FOLLOW-UP OF 26.5 MONTHS.
|
JAZZ PHARMACEUTICALS AND ZYMEWORKS ANNOUNCE 84% OVERALL SURVIVAL AT 18 MONTHS FROM PHASE 2 TRIAL EVALUATING ZANIDATAMAB IN HER2-EXPRESSING METASTATIC GASTROESOPHAGEAL ADENOCARCINOMA
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2023-01-04 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING NOVEL, MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED UPDATED KEY STRATEGIC PRIORITIES AND PROVIDED UPDATED FINANCIAL GUIDANCE FOR THE 2023 CALENDAR YEAR.
|
ZYMEWORKS PROVIDES CORPORATE UPDATE ON KEY STRATEGIC PRIORITIES AND OUTLOOK FOR 2023
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-21 07:30:00
| null |
FOLLOWS POSITIVE TOP-LINE CLINICAL DATA READOUT FROM HERIZON-BTC-01 PIVOTAL TRIAL IN BILIARY TRACT CANCERS DUBLIN AND VANCOUVER, BC , DEC. 21, 2022 /PRNEWSWIRE/ -- JAZZ PHARMACEUTICALS PLC (NASDAQ: JAZZ) AND ZYMEWORKS INC. (NASDAQ: ZYME) TODAY ANNOUNCED THAT JAZZ HAS EXERCISED ITS OPTION TO CONTINUE WITH ITS EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ZYMEWORKS' ZANIDATAMAB IN KEY MARKETS, INCLUDING THE U.S., EUROPE AND JAPAN, PURSUANT TO THE LICENSE AND COLLABORATION AGREEMENT ENTERED INTO IN OCTOBER 2022. THE DECISION TO EXERCISE THIS OPTION FOLLOWS POSITIVE TOP-LINE CLINICAL DATA FROM HERIZON-BTC-01, A PIVOTAL TRIAL IN PREVIOUSLY TREATED HER2-AMPLIFIED BILIARY TRACT CANCERS (BTC), WHICH DEMONSTRATED THAT 41.3% (95% CI: 30.4, 52.8) OF ENROLLED PATIENTS WITH HER2-AMPLIFIED AND EXPRESSING (IHC2+ AND 3+) DISEASE ACHIEVED AN OBJECTIVE RESPONSE AS ASSESSED BY INDEPENDENT CENTRAL REVIEW.
|
JAZZ PHARMACEUTICALS AND ZYMEWORKS ANNOUNCE JAZZ HAS CONFIRMED OPT-IN AND ADVANCES PARTNERSHIP FOR ZANIDATAMAB
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-19 07:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NASDAQ: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE PIVOTAL PHASE 2B HERIZON-BTC-01 OPEN-LABEL, SINGLE-ARM CLINICAL TRIAL INVESTIGATING ZANIDATAMAB, A HER2-TARGETED BISPECIFIC ANTIBODY, AS MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED HER2-AMPLIFIED AND EXPRESSING BTC.
|
ZYMEWORKS ANNOUNCES POSITIVE TOPLINE DATA IN THE PIVOTAL HERIZON-BTC-01 TRIAL OF ZANIDATAMAB
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-14 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE UPCOMING PRESENTATION OF MATURE PHASE 2 DATA EVALUATING ZANIDATAMAB IN COMBINATION WITH CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR HER2-POSITIVE GASTROESOPHAGEAL ADENOCARCINOMA (GEA) AT THE ASCO GASTROINTESTINAL CANCERS SYMPOSIUM, TAKING PLACE IN SAN FRANCISCO, CA AND VIRTUALLY ON JANUARY 19-21, 2023.
|
ZANIDATAMAB CLINICAL DATA SELECTED FOR PRESENTATION AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) GASTROINTESTINAL CANCERS SYMPOSIUM
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-12-09 08:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY PRESENTED NEW CLINICAL DATA FOR ZANIDATAMAB, THE COMPANY'S INVESTIGATIONAL HER2-TARGETED BISPECIFIC ANTIBODY, IN COMBINATION WITH PALBOCICLIB, A CDK4/6 INHIBITOR, AND FULVESTRANT, A SELECTIVE ESTROGEN RECEPTOR DEGRADER, IN PATIENTS WITH HEAVILY PRETREATED HER2-POSITIVE HORMONE-RECEPTOR POSITIVE METASTATIC BREAST CANCER. THE DATA WERE PRESENTED TODAY IN A SPOTLIGHT POSTER SESSION ENTITLED TREATMENT OF HER2-POSITIVE (HER2+) HORMONE-RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER (MBC) WITH THE NOVEL COMBINATION OF ZANIDATAMAB, PALBOCICLIB, AND FULVESTRANT DURING THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS) TAKING PLACE IN SAN ANTONIO, TEXAS AND VIRTUALLY.
|
NEW CLINICAL DATA FOR ZANIDATAMAB IN HER2+ /HR+ METASTATIC BREAST CANCER PRESENTED TODAY AT 2022 SABCS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-29 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT THE WAITING PERIOD UNDER THE HART-SCOTT-RODINO (HSR) ANTITRUST IMPROVEMENTS ACT OF 1976, AS AMENDED, FOR THE PREVIOUSLY ANNOUNCED LICENSE AGREEMENT OF ZANIDATAMAB, A HER2-TARGETED BISPECIFIC ANTIBODY, WITH JAZZ PHARMACEUTICALS HAS EXPIRED.
|
ZYMEWORKS ANNOUNCES EXPIRATION OF HART-SCOTT-RODINO WAITING PERIOD FOR ZANIDATAMAB LICENSE AGREEMENT WITH JAZZ PHARMACEUTICALS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-21 09:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--( BUSINESS WIRE )--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE PUBLICATION OF AN ABSTRACT HIGHLIGHTING NEW CLINICAL DATA FOR ZANIDATAMAB, A HER2-TARGETED BISPECIFIC ANTIBODY. ZANIDATAMAB IN COMBINATION WITH PALBOCICLIB AND FULVESTRANT WAS WELL TOLERATED, WITH ENCOURAGING AND DURABLE ANTITUMOR ACTIVITY IN HEAVILY PRETREATED PATIENTS WITH HER2-POSITIVE HR+ BREAST CANCER. A POSTER WITH AN UPDATED AND EXPANDED DATA SET WILL BE PRESENTED AT SABCS TAKING PLACE IN SAN ANTONIO, TEXAS AND VIRTUALLY ON DECEMBER 6-9, 2022.
|
ZYMEWORKS ANNOUNCES ABSTRACT FOR ZANIDATAMAB IN LATE-LINE HER2-POSITIVE HORMONE-RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER AT THE SAN ANTONIO BREAST CANCER SYMPOSIUM (SABCS)
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-11-08 16:22:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2022.
|
ZYMEWORKS PROVIDES CORPORATE UPDATE AND REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-20 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE HIGHLIGHTS FROM ITS EARLY R&D DAY REVIEWING THE COMPANY'S PROGRESS AND PLANS FOR THE DEVELOPMENT OF ITS NOVEL PIPELINE ASSETS AND APPLICATIONS OF ITS PROPRIETARY NEXT-GENERATION TECHNOLOGY PLATFORMS.
|
ZYMEWORKS EARLY R&D DAY HIGHLIGHTS PROGRESS IN DEVELOPMENT OF NOVEL PIPELINE ASSETS AND APPLICATIONS OF PROPRIETARY NEXT-GENERATION TECHNOLOGY PLATFORMS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-19 06:00:00
| null |
JAZZ TO OBTAIN EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION RIGHTS IN KEY MARKETS INCLUDING THE U.S., EUROPE AND JAPAN ZYMEWORKS TO RECEIVE $50 MILLION UPFRONT PAYMENT, A SECOND PAYMENT OF $325 MILLION, AT JAZZ'S OPTION, AND FURTHER POTENTIAL REGULATORY AND COMMERCIAL MILESTONES FOR TOTAL POTENTIAL PAYMENTS OF UP TO $1.76 BILLION, PLUS ROYALTIES ON NET SALES JAZZ CONTINUES TO EXPAND ONCOLOGY PORTFOLIO WITH NOVEL LATE-STAGE ASSET WITH COMPELLING ANTI-TUMOR ACTIVITY TOP-LINE CLINICAL DATA FOR ZANIDATAMAB IN BILIARY TRACT CANCER (HERIZON-BTC-01) EXPECTED BY END OF 2022; POTENTIAL TO SUPPORT FIRST GLOBAL REGULATORY FILINGS DUBLIN AND VANCOUVER , OCT. 19, 2022 /PRNEWSWIRE/ -- JAZZ PHARMACEUTICALS PLC (NASDAQ: JAZZ) AND ZYMEWORKS INC. (NYSE: ZYME) TODAY ANNOUNCED THAT JAZZ AND ZYMEWORKS' SUBSIDIARY, ZYMEWORKS BC INC., HAVE ENTERED INTO AN EXCLUSIVE LICENSING AGREEMENT UNDER WHICH JAZZ WILL ACQUIRE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO ZYMEWORKS' ZANIDATAMAB ACROSS ALL INDICATIONS IN THE UNITED STATES, EUROPE, JAPAN AND ALL OTHER TERRITORIES EXCEPT FOR THOSE ASIA/PACIFIC TERRITORIES PREVIOUSLY LICENSED BY ZYMEWORKS. "ZANIDATAMAB IS A NOVEL HER2-TARGETED BISPECIFIC ANTIBODY WITH BIPARATOPIC BINDING AND THE POTENTIAL TO TRANSFORM THE CURRENT STANDARD OF CARE IN MULTIPLE HER2 EXPRESSING CANCERS," SAID ROB IANNONE, M.D.
|
JAZZ PHARMACEUTICALS AND ZYMEWORKS ANNOUNCE EXCLUSIVE LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE ZANIDATAMAB, A HER2-TARGETED BISPECIFIC ANTIBODY
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-13 07:00:00
| null |
VANCOUVER, BRITISH COLUMBIA--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE COMPLETION OF ITS PREVIOUSLY ANNOUNCED INTENTION TO COMPLETE A SERIES OF TRANSACTIONS (THE “REDOMICILE TRANSACTIONS”), RESULTING IN THE FOLLOWING: (I) ZYMEWORKS DELAWARE INC. (RENAMED AS ZYMEWORKS INC.) (“NEW ZYMEWORKS”) BECOMING THE ULTIMATE PARENT COMPANY INCORPORATED IN DELAWARE; (I
|
ZYMEWORKS COMPLETES PLAN TO BECOME DELAWARE CORPORATION
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-07 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, IS PLEASED TO ANNOUNCE THAT THE COMPANY'S SECURITYHOLDERS HAVE APPROVED ITS PLAN TO BECOME A DELAWARE CORPORATION (THE “REDOMICILE”) AT THE SPECIAL MEETING OF ZYMEWORKS SECURITYHOLDERS (THE “SPECIAL MEETING”) HELD IN VANCOUVER, BC, ON OCTOBER 7, 2022. AT THE SPECIAL MEETING, A TOTAL OF 30,955,01
|
ZYMEWORKS ANNOUNCES RESULTS OF SPECIAL MEETING
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-10-04 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE, WASH.--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, REMINDS SHAREHOLDERS THAT THE DEADLINE FOR VOTING FOR THE COMPANY'S PLAN TO BECOME A DELAWARE CORPORATION (THE “REDOMICILE”) IS 9:00 A.M., PACIFIC TIME, ON OCTOBER 5, 2022. IF YOU REQUIRE ASSISTANCE VOTING YOUR PROXY, PLEASE CONTACT KINGSDALE ADVISORS AT 1-855-476-7981 (WITHIN NORTH AMERI
|
ZYMEWORKS REMINDS SHAREHOLDERS TO VOTE FOR ITS REDOMICILE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-26 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, IS PLEASED TO ANNOUNCE THAT A SECOND INDEPENDENT PROXY ADVISORY FIRM, INSTITUTIONAL SHAREHOLDER SERVICES INC. (“ISS”), HAS RECOMMENDED SHAREHOLDERS VOTE FOR THE COMPANY'S PLAN TO BECOME A DELAWARE CORPORATION (THE “REDOMICILE”). ISS' POSITIVE RECOMMENDATION FOLLOWS GLASS, LEWIS & CO.'S (“GLA
|
INDEPENDENT PROXY ADVISORY FIRM ISS RECOMMENDS A VOTE FOR THE ZYMEWORKS REDOMICILE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-16 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT INDEPENDENT PROXY ADVISORY FIRM GLASS, LEWIS & CO. (“GLASS LEWIS”) HAS RECOMMENDED THAT ZYMEWORKS SHAREHOLDERS VOTE FOR THE COMPANY'S PLAN TO BECOME A DELAWARE CORPORATION (THE “REDOMICILE”). IN ITS REPORT, GLASS LEWIS STATES THAT ZYMEWORKS' CASE FOR THE REDOMICILE IS “C
|
INDEPENDENT PROXY ADVISORY FIRM GLASS LEWIS RECOMMENDS ZYMEWORKS SHAREHOLDERS VOTE FOR REDOMICILE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-12 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY PRESENTED PRELIMINARY RESULTS FROM THE COMPANY'S PHASE 1 CLINICAL TRIAL EVALUATING ZANIDATAMAB ZOVODOTIN (ZW49) FOR THE TREATMENT OF HER2-POSITIVE TUMORS. THE PRESENTATION, ENTITLED “PRELIMINARY RESULTS FROM A PHASE 1 STUDY USING THE BISPECIFIC, HUMAN EPIDERMAL GROWTH FACTOR 2 (HER2)-TARGETING ANTIBODY-DRUG CONJUGATE (A
|
ZYMEWORKS REPORTS PRELIMINARY PHASE 1 TRIAL RESULTS FOR ZANIDATAMAB ZOVODOTIN (ZW49) AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY ANNUAL CONGRESS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-08 16:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT THE PROXY STATEMENT (“PROXY STATEMENT”) AND RELATED MATERIALS, DATED SEPTEMBER 2, 2022 FOR ITS SPECIAL MEETING OF SECURITYHOLDERS (THE “SPECIAL MEETING”) HAVE BEEN FILED PUBLICLY AND ARE BEING MAILED TO SECURITYHOLDERS. THE SPECIAL MEETING WILL BE HELD ON FRIDAY, OCTOBER 7,
|
ZYMEWORKS ANNOUNCES FILING AND MAILING OF MATERIALS FOR THE SPECIAL MEETING TO APPROVE REDOMICILE TO DELAWARE
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-09-04 18:05:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE RELEASE OF AN ABSTRACT BY ESMO WITH PRELIMINARY RESULTS FROM THE COMPANY'S PHASE 1 STUDY OF ZANIDATAMAB ZOVODOTIN (ZW49), AN INVESTIGATIONAL NOVEL BISPECIFIC HER2 TARGETED ANTIBODY-DRUG CONJUGATE. RESULTS FROM THE STUDY ENTITLED “PRELIMINARY RESULTS FROM A PHASE 1 STUDY USING THE BISPECIFIC, HUMAN EPIDERMA
|
ZYMEWORKS ANNOUNCES RELEASE OF ESMO ABSTRACT FOR PHASE 1 STUDY OF ZANIDATAMAB ZOVODOTIN (ZW49) IN SOLID CANCERS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-22 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY REPORTED, AS REQUIRED BY THE NEW YORK STOCK EXCHANGE LISTED COMPANY MANUAL RULE 303A.08 (THE “NYSE RULE”), AN EQUITY INDUCEMENT AWARD TO DR. PAUL MOORE, ZYMEWORKS' NEW CHIEF SCIENTIFIC OFFICER. IN ACCORDANCE WITH THE NYSE RULE, ZYMEWORKS APPROVED THE GRANT OF THE FOLLOWING EQUITY AWARD TO DR. MOORE AS A MATERIAL INDUCEM
|
ZYMEWORKS REPORTS INDUCEMENT GRANT TO NEW CHIEF SCIENTIFIC OFFICER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-07-15 08:00:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (“ZYMEWORKS” OR THE “COMPANY”) (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED ITS INTENTION TO BECOME A DELAWARE CORPORATION (“NEW ZYMEWORKS”), SUBJECT TO RECEIPT OF NECESSARY SHAREHOLDER, STOCK EXCHANGE, AND COURT APPROVALS. ZYMEWORKS BELIEVES THAT BECOMING A DELAWARE CORPORATION (THE “REDOMICILE”) WILL ENHANCE LONG-TERM VALUE FOR SHAREHOLDERS, HELP REDUC
|
ZYMEWORKS ANNOUNCES PLAN TO BECOME A DELAWARE CORPORATION
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-27 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT IT IS STRENGTHENING ITS SENIOR LEADERSHIP TEAM WITH THE APPOINTMENT OF PAUL MOORE, PH.D., AS CHIEF SCIENTIFIC OFFICER, REPORTING DIRECTLY TO THE CHIEF EXECUTIVE OFFICER. DR. MOORE BRINGS MORE THAN 25 YEARS OF US-BASED EXPERIENCE IN BIOLOGICS DRUG DISCOVERY AND DEVELOPMENT IN BIOTECHNOLOGY
|
ZYMEWORKS APPOINTS DR. PAUL MOORE AS CHIEF SCIENTIFIC OFFICER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-06-10 09:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS (THE “BOARD”) HAS ADOPTED A LIMITED-DURATION SHAREHOLDER RIGHTS PLAN (THE “RIGHTS PLAN”). THE BOARD ADOPTED THE RIGHTS PLAN IN RESPONSE TO THE UNSOLICITED, NON-BINDING PROPOSAL BY ALL BLUE FALCONS FZE (“ALL BLUE”) TO ACQUIRE ZYMEWORKS AND ALL BLUE'S CONTINUED SHARE A
|
ZYMEWORKS ADOPTS LIMITED-DURATION SHAREHOLDER RIGHTS PLAN, ENABLING ALL SHAREHOLDERS TO REALIZE FULL VALUE OF COMPANY
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-26 17:00:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED NEW CLINICAL DATA FOR THE HER2‑TARGETED BISPECIFIC ANTIBODY ZANIDATAMAB IN BOTH HER2-POSITIVE BREAST CANCER AND GASTRIC/GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA. THE DATA ARE BEING PRESENTED IN TWO SEPARATE POSTER SESSIONS AT THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING JUNE
|
CLINICAL DATA DEMONSTRATING PROMISING ANTITUMOR ACTIVITY WITH ZANIDATAMAB IN 1L SETTING OF HER2‑POSITIVE BREAST AND GASTROESOPHAGEAL CANCERS TO BE PRESENTED AT ASCO 2022
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-20 09:15:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS, AFTER THOROUGH CONSULTATION WITH ITS FINANCIAL AND LEGAL ADVISORS, UNANIMOUSLY DETERMINED THAT THE UNSOLICITED, OPPORTUNISTIC, NON-BINDING PROPOSAL FROM AN ACTIVIST SHAREHOLDER, ALL BLUE FALCONS FZE (“ALL BLUE”), AND ITS AFFILIATES TO PURCHASE ZYMEWORKS FOR $10.50 P
|
ZYMEWORKS' BOARD OF DIRECTORS UNANIMOUSLY REJECTS UNSOLICITED, NON-BINDING PROPOSAL
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-19 13:00:00
| null |
SIDDHARTHA MUKHERJEE, MD, HEMATOLOGY AND ONCOLOGY MEDICAL EXPERT, RHODES SCHOLAR AND PULITZER PRIZE WINNING AUTHOR, RECENTLY JOINED ALL BLUE AS MEDICAL ADVISOR ALL BLUE URGES ZYMEWORKS BOARD TO ENGAGE WITH ALL BLUE ON ITS COMPELLING $10.50 PER SHARE ACQUISITION PROPOSAL, CONSISTENT WITH THE BOARD'S FIDUCIARY DUTIES DUBAI, UNITED ARAB EMIRATES , MAY 19, 2022 /PRNEWSWIRE/ -- ALL BLUE CAPITAL ("AB"), A GLOBAL INVESTMENT FIRM, TODAY ANNOUNCED THAT SIDDHARTHA MUKHERJEE, MD, ASSOCIATE PROFESSOR OF MEDICINE IN THE DIVISION OF HEMATOLOGY/ONCOLOGY AT COLUMBIA UNIVERSITY MEDICAL CENTER IN NEW YORK CITY, RECENTLY JOINED AB AS MEDICAL ADVISOR. AS A PULITZER PRIZE WINNING AUTHOR, RHODES SCHOLAR AND RECIPIENT OF THE PADMA SHRI, THE FOURTH HIGHEST CIVILIAN AWARD CONFERRED BY THE GOVERNMENT OF INDIA, DR. MUKHERJEE WOULD APPLY HIS EXTENSIVE MEDICAL EXPERTISE AS A MEMBER OF THE ZYMEWORKS (NYSE: ZYME) BOARD OF DIRECTORS FOLLOWING A SUCCESSFUL COMPLETION OF AB'S PROPOSED $10.50 PER SHARE IN CASH ACQUISITION OF ZYMEWORKS.
|
ALL BLUE CAPITAL EXPANDS ITS LEADERSHIP TEAM TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS INC.
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-05-03 15:27:00
| null |
ALAN BARGE, MD, ONCOLOGY AND BIOPHARMACEUTICAL DRUG DEVELOPMENT EXPERT, FORMER HEAD OF ONCOLOGY AT ASTRAZENECA, RECENTLY JOINED ALL BLUE AS ONCOLOGY DRUG DEVELOPMENT ADVISOR BARGE'S EXPERTISE AND FOCUSED LEADERSHIP TO FOSTER TURNAROUND OF ZYMEWORKS' OPERATING PERFORMANCE DUBAI, UNITED ARAB EMIRATES , MAY 3, 2022 /PRNEWSWIRE/ -- ALL BLUE CAPITAL ("AB"), A GLOBAL INVESTMENT FIRM, TODAY ANNOUNCED THAT BIOPHARMACEUTICAL INDUSTRY LEADER AND EXPERT, ALAN BARGE, MD, HAS AGREED TO ADVISE THE FIRM AS ONCOLOGY DRUG DEVELOPMENT ADVISOR. IN THIS CAPACITY, DR. BARGE IS PREPARED TO PROVIDE THE EXPERTISE, FOCUSED LEADERSHIP AND BUSINESS ACUMEN NECESSARY TO SUPPORT AB'S RECENT PROPOSAL TO ACQUIRE ZYMEWORKS, INC. (NYSE: ZYME), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY, WITH THE GOAL OF REVERSING THE VALUE-DESTRUCTIVE MEASURES THAT ZYMEWORKS AND ITS BOARD OF DIRECTORS IMPLEMENTED OVER THE PAST 12 MONTHS.
|
ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC.
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-28 21:00:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)---- $ZYME--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY CONFIRMED IT HAS RECEIVED AN UNSOLICITED, NON-BINDING PROPOSAL FROM ALL BLUE FALCONS FZE (“ABF”) AND ITS AFFILIATES TO PURCHASE THE COMPANY FOR $10.50 PER SHARE IN CASH. THE ZYMEWORKS BOARD OF DIRECTORS WILL CAREFULLY REVIEW THE PROPOSAL TO DETERMINE THE COURSE OF ACTION THAT IT BELIEVES IS IN THE BEST I
|
ZYMEWORKS CONFIRMS RECEIPT OF UNSOLICITED, NON-BINDING PROPOSAL FROM ALL BLUE FALCONS
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-04-28 08:30:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING NEXT-GENERATION MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMPLETED ENROLLMENT IN ITS GLOBAL HERIZON-BTC-01 PIVOTAL CLINICAL TRIAL EVALUATING THE ANTITUMOR ACTIVITY OF ZANIDATAMAB MONOTHERAPY IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED OR METASTATIC HER2-AMPLIFIED BILIARY TRACT CANCERS (BTC), INCLUDING GALLBLADDER CANCER AND CHOLANGIOCARC
|
ZYMEWORKS REPORTS LAST PATIENT ENROLLED IN PIVOTAL STUDY OF ZANIDATAMAB IN TREATMENT OF HER2-EXPRESSING LATE-LINE BILIARY TRACT CANCER
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-31 12:05:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 11,035,000 COMMON SHARES, INCLUDING THE EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE 1,875,000 ADDITIONAL SHARES, AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 3,340,000 COMMON SHARES
|
ZYMEWORKS ANNOUNCES CLOSING OF PUBLIC OFFERING AND EXERCISE IN FULL OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-26 21:36:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN PUBLIC OFFERING OF 9,160,000 COMMON SHARES AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 3,340,000 COMMON SHARES. THE COMMON SHARES ARE BEING OFFERED AT A PUBLIC OFFERING PRICE OF $8.00 PER COMMON SHARE AND THE PRE-FUNDED WARRANTS ARE
|
ZYMEWORKS ANNOUNCES PRICING OF $100.0 MILLION PUBLIC OFFERING
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Press Release 0 2CRSI.PA
1 2CRSI.PA
2 2CRSI.PA
3 2CRSI.PA
4 2CRSI.PA
...
83 ZYXI
84 ZYXI
85 ZYXI
0 ZZZ.TO
1 ZZZ.TO
Name: symbol, Length: 320040, dtype: object
|
2022-01-26 16:01:00
| null |
VANCOUVER, BRITISH COLUMBIA & SEATTLE--(BUSINESS WIRE)--ZYMEWORKS INC. (NYSE: ZYME), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING MULTIFUNCTIONAL BIOTHERAPEUTICS, TODAY ANNOUNCED THAT IT HAS COMMENCED AN UNDERWRITTEN PUBLIC OFFERING OF ITS COMMON SHARES AND, IN LIEU OF COMMON SHARES TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE ITS COMMON SHARES. THE PROPOSED OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY
|
ZYMEWORKS ANNOUNCES PROPOSED PUBLIC OFFERING
|
ZYME
|
a5c0a04e-eb88-4264-9cb2-fb3140e63537
|
PressRelease
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.